In connection with the implementation of the project under the working title ‘Design and development of nanoparticle-RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids’, by BS Biotechna SA (hereinafter referred to as the Ordering Party), for which the Ordering Party is applying for funding under the Competition for the development of targeted or personalised medicine based on medicinal products based on nucleic acids and small molecules No. ABM/ 2022/6 conducted by the Medical Research Agency, the Ordering Party announces a procedure for the implementation of the service of optimisation, production and analysis of liposomal siRNA formulations.
Please be advised that Request for Quotation No. 3/2023 of 10 February 2023 has been amended in Section V. Conditions for participation in the procedure and grounds for exclusion. This amendment does not affect the deadline for submission of tenders.
Please familiarise yourself with the amended Request for Proposals No. 3/2023 and the Bid Form, which constitutes Appendix 1 to the Request for Proposals.
Attachments to download:
Market research 3/2023 (DOCX, 435 KB)
Offer form 3/2023 (DOCX, 137 KB)
NDA version 1 (DOCX, 442 KB)
NDA version 2 (DOCX, 821 KB)
Market research 3/2023_update (DOCX, 554 KB)
Offer form 3/2023_update (DOCX, 272 KB)